An antibody against the extracellular domain of LPP3 inhibits cell-cell interactions and angiogenesis in vitro.
| Institute |
|---|
| University of Illinois Chicago |
| Cat. #: | 156376 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer;Cell biology;Cell signaling and signal transduction |
| Application: | FACS ; IP ; WB |
| Target: | Lipid Phosphate Phosphohydrolase 3 |
| Reactivity: | Human ; Mouse |
| Host: | Mouse |
| Class: | Monoclonal |
| Alternate name: | PLPP3, Dri42, PAP2B, VCIP, PPAP2B or phospholipid phosphatase 3 |
|---|---|
| Product description: | An antibody against the extracellular domain of LPP3 inhibits cell-cell interactions and angiogenesis in vitro. In addition, LPP3 not only catalyzes the dephosphorylation of the bioactive lipid sphingosine-1-phosphate (S1P) to generate sphingosine but also may regulate embryonic development and angiogenesis via the Wnt pathway. LPP3 also has the ability to potentiate tumor growth by amplifying B-catenin and CYCLIN-D1 activities. Thus, LPP3 is a potential target for inhibiting the growth of glioblastoma, an aggressive type of brain tumor, and other LPP3-expressing tumors. This may serve as a link in the acquisition of proliferative, invasive, and metastatic phenotypes. |
| Conjugation: | Unconjugated |
| Immunogen: | A modified synthetic peptide (YRCRGDDSKVQEARKSFFc-KLH) corresponding to 179-196 of human LPP3 conjugated to keyhole limpet hemocyanin |
| Target background: | An antibody against the extracellular domain of LPP3 inhibits cell-cell interactions and angiogenesis in vitro. In addition, LPP3 not only catalyzes the dephosphorylation of the bioactive lipid sphingosine-1-phosphate (S1P) to generate sphingosine but also may regulate embryonic development and angiogenesis via the Wnt pathway. LPP3 also has the ability to potentiate tumor growth by amplifying B-catenin and CYCLIN-D1 activities. Thus, LPP3 is a potential target for inhibiting the growth of glioblastoma, an aggressive type of brain tumor, and other LPP3-expressing tumors. This may serve as a link in the acquisition of proliferative, invasive, and metastatic phenotypes. |
|---|
| Format: | Liquid |
|---|---|
| Shipping conditions: | Dry ice |
| References: |
Humtsoe et al. 2010. Mol Cell Biol. 30(7):1593-606. PMID: 20123964. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151015 | Anti-CyclinA [E70.1] |
Key Info
Anti-CyclinA [E70.1]
|
View Tool | |||||||||||||||||||
| 151021 | Anti-CyclinB1 [V152] |
Key Info
Anti-CyclinB1 [V152]
|
View Tool | |||||||||||||||||||
| 151024 | Anti-Hairy [1/24] |
Key Info
Anti-Hairy [1/24]
|
View Tool | |||||||||||||||||||
| 151035 | Anti-CD8 [14] mAb |
Key Info
Anti-CD8 [14] mAb
|
View Tool | |||||||||||||||||||
| 151036 | Anti-ICAM1 [15.2] |
Key Info
Anti-ICAM1 [15.2]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.